Pre-diagnosis plasma cell-free DNA reveals early signatures of prostate and breast cancer risk up to eight years prior to clinical detection.

Pre-diagnosis plasma cell-free DNA methylation signatures predict prostate and breast cancer risk up to eight years before clinical detection, with hazard ratios of 3.55 and 2.3 respectively.

• Why it matters: Early detection of cancer risk can enable preventive interventions and improve patient outcomes, but current methods lack reliable early biomarkers. Identifying preclinical epigenetic changes offers a promising avenue for early risk assessment.
• What they did: Genome-wide cfDNA methylation profiling was performed on 491 plasma samples collected up to nine years prior to diagnosis, revealing cancer-associated epigenetic alterations and predictive signatures through statistical modeling.
• The result: The study demonstrates that cfDNA methylation patterns, especially in silencer regions, can robustly forecast future prostate and breast cancer risk, paving the way for improved early detection and surveillance strategies.